miRdetect
The company develops and distributes the M371-Test, a liquid biopsy diagnostic tool designed for the primary diagnosis and follow-up care of testicular cancer. The test utilizes a blood sample to detect the tumor-specific microRNA miR-371a-3p, which is secreted by germ cell tumors into the bloodstream. It serves medical laboratories and healthcare providers as a highly sensitive alternative to traditional serum markers and radiation-heavy CT scans.
Healthtech
Biotechnology
Diagnostics
Funding summary
- Total raised
- €0
- Funding rounds
- 1
Investors in miRdetect
Investors on record for miRdetect. Click any investor to view their CAPLINK profile and funding criteria.
Fundraising for a startup like miRdetect?
Explore CAPLINK's investor database of thousands of active VCs and angels.
Browse investors